High phosphorus diet induces vascular calcification, a related decrease in bone mass and changes in the aortic gene expression

Bone

Volumn 46, Issue 1, 2010, Pages 121-128

  Román García, Pablo ^a   Carrillo López, Natalia ^a   Fernández Martín, José Luis ^a   Naves Díaz, Manuel ^a   Ruiz Torres, María Piedad ^b   Cannata Andía, Jorge B ^a  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Bone mass; High phosphorus diet; Vascular calcification; Vascular wall gene expression; Wnt pathway inhibitors

Indexed keywords

ALPHA TROPOMYOSIN; CATHEPSIN K; CREATININE; ELASTIN; FRIZZLED PROTEIN; PARATHYROID HORMONE; PHOSPHORUS; SECRETED FRIZZLED RELATED PROTEIN 1; SECRETED FRIZZLED RELATED PROTEIN 2; SECRETED FRIZZLED RELATED PROTEIN 4; WNT PROTEIN;

ABDOMINAL AORTA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL CALCIFICATION; BONE DENSITY; BONE MASS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENE REPRESSION; HISTOLOGY; HYPERPHOSPHATEMIA; MALE; MICROARRAY ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; OSSIFICATION; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PHOSPHATE INTAKE; RAT; SIGNAL TRANSDUCTION; UNINDEXED SEQUENCE;

ANIMALS; AORTA; BONE AND BONES; BONE DENSITY; CALCINOSIS; DENSITOMETRY; GENE EXPRESSION; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHORUS; RATS; RATS, WISTAR; VASCULAR DISEASES;

EID: 72049126357     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2009.09.006     Document Type: Article

References (49)

1. Cannata-Andia J.B., Rodriguez-Garcia M., Carrillo-Lopez N., Naves-Diaz M., and Diaz-Lopez B. Vascular calcifications: pathogenesis, management, and impact on clinical outcomes. J. Am. Soc. Nephrol. 17 (2006) S267-S273
2. Moe S.M., and Chen N.X. Mechanisms of vascular calcification in chronic kidney disease. J. Am. Soc. Nephrol. 19 (2008) 213-216
3. Cannata-Andia J.B., and Rodriguez-Garcia M. Hyperphosphataemia as a cardiovascular risk factor-how to manage the problem. Nephrol. Dial. Transplant. 17 Suppl. 11 (2002) 16-19
4. Block G.A., and Port F.K. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am. J. Kidney Dis. 35 (2000) 1226-1237
5. Schoppet M., Shroff R.C., Hofbauer L.C., and Shanahan C.M. Exploring the biology of vascular calcification in chronic kidney disease: what's circulating?. Kidney Int. 73 (2008) 384-390
6. Giachelli C.M. Vascular calcification mechanisms. J. Am. Soc. Nephrol. 15 (2004) 2959-2964
7. Reynolds J.L., Joannides A.J., Skepper J.N., McNair R., Schurgers L.J., Proudfoot D., et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J. Am. Soc. Nephrol. 15 (2004) 2857-2867
8. Neven E., Dauwe S., De Broe M.E., D'Haese P.C., and Persy V. Endochondral bone formation is involved in media calcification in rats and in men. Kidney Int. 72 (2007) 574-581
9. Shao J.S., Cai J., and Towler D.A. Molecular mechanisms of vascular calcification: lessons learned from the aorta. Arterioscler. Thromb. Vasc. Biol. 26 (2006) 1423-1430
10. Rodriguez-Garcia M., Gomez-Alonso C., Naves-Diaz M., Diaz-Lopez J.B., Diaz-Corte C., and Cannata-Andia J.B. Vascular calcifications, vertebral fractures and mortality in haemodialysis patients. Nephrol. Dial. Transplant. 24 (2009) 239-246
11. Naves M., Rodriguez-Garcia M., Diaz-Lopez J.B., Gomez-Alonso C., and Cannata-Andia J.B. Progression of vascular calcifications is associated with greater bone loss and increased bone fractures. Osteoporos. Int. 19 (2008) 1161-1166
12. Ormrod D., and Miller T. Experimental uremia. Description of a model producing varying degrees of stable uremia. Nephron 26 (1980) 249-254
13. Gomez-Alonso C., Menendez-Rodriguez P., Virgos-Soriano M.J., Fernandez-Martin J.L., Fernandez-Coto M.T., and Cannata-Andia J.B. Aluminum-induced osteogenesis in osteopenic rats with normal renal function. Calcif. Tissue Int. 64 (1999) 534-541
14. Alvarez-Garcia O., Carbajo-Perez E., Garcia E., Gil H., Molinos I., Rodriguez J., et al. Rapamycin retards growth and causes marked alterations in the growth plate of young rats. Pediatr. Nephrol. 22 (2007) 954-961
15. Li C., and Wong W.H. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 31-36
16. Carrillo-Lopez N., Alvarez-Hernandez D., Gonzalez-Suarez I., Roman-Garcia P., Valdivielso J.M., Fernandez-Martin J.L., et al. Simultaneous changes in the calcium-sensing receptor and the vitamin D receptor under the influence of calcium and calcitriol. Nephrol. Dial. Transplant. 23 (2008) 3479-3484
17. Lee H.K., Braynen W., Keshav K., and Pavlidis P. ErmineJ: tool for functional analysis of gene expression data sets. BMC Bioinformatics 6 (2005) 269
18. Kawano Y., and Kypta R. Secreted antagonists of the Wnt signalling pathway. J. Cell. Sci. 116 (2003) 2627-2634
19. Matias P.J., Ferreira C., Jorge C., Borges M., Aires I., Amaral T., et al. 25-Hydroxyvitamin D3, arterial calcifications and cardiovascular risk markers in haemodialysis patients. Nephrol. Dial. Transplant. 24 (2009) 611-618
20. Naves-Diaz M., Alvarez-Hernandez D., Passlick-Deetjen J., Guinsburg A., Marelli C., Rodriguez-Puyol D., et al. Oral active vitamin D is associated with improved survival in hemodialysis patients. Kidney Int. 74 (2008) 1070-1078
21. London G.M., Marchais S.J., Guerin A.P., Boutouyrie P., Metivier F., and de Vernejoul M.C. Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD. J. Am. Soc. Nephrol. 19 (2008) 1827-1835
22. Moe S., Drueke T., Cunningham J., Goodman W., Martin K., Olgaard K., et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int. 69 (2006) 1945-1953
23. Moe S.M., and Chen N.X. Pathophysiology of vascular calcification in chronic kidney disease. Circ. Res. 95 (2004) 560-567
24. Almaden Y., Canalejo A., Hernandez A., Ballesteros E., Garcia-Navarro S., Torres A., et al. Direct effect of phosphorus on PTH secretion from whole rat parathyroid glands in vitro. J. Bone Miner. Res. 11 (1996) 970-976
25. Huttunen M.M., Tillman I., Viljakainen H.T., Tuukkanen J., Peng Z., Pekkinen M., et al. High dietary phosphate intake reduces bone strength in the growing rat skeleton. J. Bone. Miner. Res. 22 (2007) 83-92
26. Roman-Garcia P., Carrillo-Lopez N., and Cannata-Andia J.B. Pathogenesis of bone and mineral related disorders in chronic kidney disease: key role of hyperphosphatemia. J. Ren. Care. 35 Suppl. 1 (2009) 34-38
27. Silver J., Kilav R., Sela-Brown A., and Naveh-Many T. Molecular mechanisms of secondary hyperparathyroidism. Pediatr. Nephrol. 14 (2000) 626-628
28. Silver J. Molecular mechanisms of secondary hyperparathyroidism. Nephrol. Dial. Transplant. 15 Suppl. 5 (2000) 2-7
29. Almaden Y., Hernandez A., Torregrosa V., Canalejo A., Sabate L., Fernandez Cruz L., et al. High phosphate level directly stimulates parathyroid hormone secretion and synthesis by human parathyroid tissue in vitro. J. Am. Soc. Nephrol. 9 (1998) 1845-1852
30. Neves K.R., Graciolli F.G., dos Reis L.M., Graciolli R.G., Neves C.L., Magalhaes A.O., et al. Vascular calcification: contribution of parathyroid hormone in renal failure. Kidney. Int. 71 (2007) 1262-1270
31. Cozzolino M., Staniforth M.E., Liapis H., Finch J., Burke S.K., Dusso A.S., et al. Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia. Kidney Int. 64 (2003) 1653-1661
32. Burke S.K. Phosphate is a uremic toxin. J. Ren. Nutr. 18 (2008) 27-32
33. Neves K.R., Graciolli F.G., dos Reis L.M., Pasqualucci C.A., Moyses R.M., and Jorgetti V. Adverse effects of hyperphosphatemia on myocardial hypertrophy, renal function, and bone in rats with renal failure. Kidney Int. 66 (2004) 2237-2244
34. Voormolen N., Noordzij M., Grootendorst D.C., Beetz I., Sijpkens Y.W., van Manen J.G., et al. High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients. Nephrol. Dial. Transplant. 22 (2007) 2909-2916
35. Adragao T., Herberth J., Monier-Faugere M.C., Branscum A.J., Ferreira A., Frazao J.M., et al. Low bone volume-a risk factor for coronary calcifications in hemodialysis patients. Clin. J. Am. Soc. Nephrol. 4 (2009) 450-455
36. Braun J., Oldendorf M., Moshage W., Heidler R., Zeitler E., and Luft F.C. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am. J. Kidney Dis. 27 (1996) 394-401
37. Raggi P., James G., Burke S.K., Bommer J., Chasan-Taber S., Holzer H., et al. Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis. J. Bone Miner. Res. 20 (2005) 764-772
38. Toussaint N.D., Lau K.K., Strauss B.J., Polkinghorne K.R., and Kerr P.G. Associations between vascular calcification, arterial stiffness and bone mineral density in chronic kidney disease. Nephrol. Dial. Transplant. 23 (2008) 586-593
39. London G.M., Marty C., Marchais S.J., Guerin A.P., Metivier F., and de Vernejoul M.C. Arterial calcifications and bone histomorphometry in end-stage renal disease. J. Am. Soc. Nephrol. 15 (2004) 1943-1951
40. Coen G., Ballanti P., Mantella D., Manni M., Lippi B., Pierantozzi A., et al. Bone turnover, osteopenia and vascular calcifications in hemodialysis patients. A histomorphometric and multislice CT study. Am. J. Nephrol. 29 (2009) 145-152
41. Bilezikian J.P. Bone strength in primary hyperparathyroidism. Osteoporos. Int. 14 Suppl. 5 (2003) S113-S115 discussion S115-7
42. Santamaria I., Alvarez-Hernandez D., Jofre R., Polo J.R., Menarguez J., and Cannata-Andia J.B. Progression of secondary hyperparathyroidism involves deregulation of genes related to DNA and RNA stability. Kidney Int. 67 (2005) 2267-2279
43. Holmen S.L., Giambernardi T.A., Zylstra C.R., Buckner-Berghuis B.D., Resau J.H., Hess J.F., et al. Decreased BMD and limb deformities in mice carrying mutations in both Lrp5 and Lrp6. J. Bone Miner. Res. 19 (2004) 2033-2040
44. Al-Aly Z., Shao J.S., Lai C.F., Huang E., Cai J., Behrmann A., et al. Aortic Msx2-Wnt calcification cascade is regulated by TNF-alpha-dependent signals in diabetic Ldlr-/- mice. Arterioscler. Thromb. Vasc. Biol. 27 (2007) 2589-2596
45. Towler D.A., Shao J.S., Cheng S.L., Pingsterhaus J.M., and Loewy A.P. Osteogenic regulation of vascular calcification. Ann. N. Y. Acad. Sci. 1068 (2006) 327-333
46. Bodine P.V., Zhao W., Kharode Y.P., Bex F.J., Lambert A.J., Goad M.B., et al. The Wnt antagonist secreted frizzled-related protein-1 is a negative regulator of trabecular bone formation in adult mice. Mol. Endocrinol. 18 (2004) 1222-1237
47. Shalhoub V., Shatzen E., Henley C., Boedigheimer M., McNinch J., Manoukian R., et al. Calcification inhibitors and Wnt signaling proteins are implicated in bovine artery smooth muscle cell calcification in the presence of phosphate and vitamin D sterols. Calcif. Tissue Int. 79 (2006) 431-442
48. Kobayashi K., Luo M., Zhang Y., Wilkes D.C., Ge G., Grieskamp T., et al. Secreted Frizzled-related protein 2 is a procollagen C proteinase enhancer with a role in fibrosis associated with myocardial infarction. Nat. Cell Biol. 11 (2009) 46-55
49. Berndt T., Craig T.A., Bowe A.E., Vassiliadis J., Reczek D., Finnegan R., et al. Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent. J. Clin. Invest. 112 (2003) 785-794